In vivo evolution of carbapenem resistance in hypervirulent Klebsiella pneumoniae in a patient undergoing long-term treatment

J Antimicrob Chemother. 2022 Feb 2;77(2):531-533. doi: 10.1093/jac/dkab380.

Authors

Na Tang^{1

2}, Jinshu Hu³, Yingying Zhao¹, Yuqin Song¹, Chao Wang¹, Gang Zhang¹, Dawei Wei^{1

2}, Hailing Fang¹, Chao Li¹, Rufu Jia³, Jie Feng¹

Affiliations

¹ State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
² College of Life Science, University of Chinese Academy of Sciences, Beijing, China.
³ Cangzhou Central Hospital, Cangzhou, China.

PMID: 34726753
DOI: 10.1093/jac/dkab380

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Carbapenems / pharmacology
Carbapenems / therapeutic use
Humans
Klebsiella Infections* / drug therapy
Klebsiella pneumoniae* / genetics

Substances

Carbapenems